Affordable Access

deepdyve-link
Publisher Website

In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19.

Authors
  • Zhang, Xiao-Jing1
  • Qin, Juan-Juan2
  • Cheng, Xu2
  • Shen, Lijun2
  • Zhao, Yan-Ci2
  • Yuan, Yufeng3
  • Lei, Fang4
  • Chen, Ming-Ming2
  • Yang, Huilin2
  • Bai, Liangjie4
  • Song, Xiaohui4
  • Lin, Lijin2
  • Xia, Meng4
  • Zhou, Feng5
  • Zhou, Jianghua2
  • She, Zhi-Gang2
  • Zhu, Lihua2
  • Ma, Xinliang6
  • Xu, Qingbo7
  • Ye, Ping8
  • And 29 more
  • 1 Department of Cardiology, Renmin Hospital, School of Basic Medical Science, Wuhan University, Wuhan, China; Institute of Model Animal, Wuhan University, Wuhan, China; Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China. , (China)
  • 2 Department of Cardiology, Renmin Hospital, School of Basic Medical Science, Wuhan University, Wuhan, China; Institute of Model Animal, Wuhan University, Wuhan, China. , (China)
  • 3 Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China. , (China)
  • 4 Institute of Model Animal, Wuhan University, Wuhan, China. , (China)
  • 5 Institute of Model Animal, Wuhan University, Wuhan, China; Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China. , (China)
  • 6 Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA 19004, USA.
  • 7 Centre for Clinic Pharmacology, The William Harvey Research Institute, Queen Mary University of London, London, UK.
  • 8 Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430072, China. , (China)
  • 9 Department of Neurology, Wuhan First Hospital/Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan 430072, China. , (China)
  • 10 Department of General Surgery, Ezhou Central Hospital, Ezhou 436000, China. , (China)
  • 11 Department of General Surgery, Huanggang Central Hospital, Huanggang 438000, China. , (China)
  • 12 Wuhan Seventh Hospital, Wuhan 430072, China. , (China)
  • 13 Department of Stomatology, Xiantao First People's Hospital, Xiantao 433000, China. , (China)
  • 14 Department of Neurology, The First People's Hospital of Jingmen Affiliated to Hubei Minzu University, Jingmen 448000, China. , (China)
  • 15 Department of Hepatobiliary and Pancreatic Surgery, Suizhou Central Hospital Affiliated to Hubei Medical College, Suizhou 441300, China. , (China)
  • 16 The Ninth Hospital of Wuhan City, Wuhan 430072, China. , (China)
  • 17 Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital and Institute of Cardiovascular Diseases, China Three Gorges University, Yichang 443000, China. , (China)
  • 18 Department of Intensive Care Unit, Wuhan Third Hospital & Tongren Hospital of Wuhan University, Wuhan, China. , (China)
  • 19 Department of Cardiology, Renmin Hospital, School of Basic Medical Science, Wuhan University, Wuhan, China; The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi 445000, China. , (China)
  • 20 Department of Hepatobiliary Surgery, The First Affiliated Hospital of Changjiang University, Jingzhou, China. , (China)
  • 21 Department of Hepatobiliary Surgery, Jingzhou Central Hospital, Jingzhou, China. , (China)
  • 22 Department of Hepatobiliary and Pancreatic Surgery, Xianning Central Hospital, Xianning, Hubei Province, China. , (China)
  • 23 Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China. , (China)
  • 24 Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. , (China)
  • 25 Department of Neonatology, Renmin Hospital of Wuhan University, Wuhan, China. , (China)
  • 26 Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada. , (Canada)
  • 27 NAFLD Research Center, Division of Gastroenterology and Epidemiology, University of California, San Diego, San Diego, CA, USA.
  • 28 Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: [email protected] , (China)
  • 29 Departments of Anesthesiology, Physiology, and Medicine, Cardiovascular Research Laboratories, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: [email protected]
  • 30 Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha 410000, China. Electronic address: [email protected] , (China)
  • 31 Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine & Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China & Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangzhou 510006, China. Electronic address: [email protected] , (China)
  • 32 Department of Cardiology, Renmin Hospital, School of Basic Medical Science, Wuhan University, Wuhan, China; Institute of Model Animal, Wuhan University, Wuhan, China; Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China; Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China. Electronic address: [email protected] , (China)
Type
Published Article
Journal
Cell metabolism
Publication Date
Aug 04, 2020
Volume
32
Issue
2
Identifiers
DOI: 10.1016/j.cmet.2020.06.015
PMID: 32592657
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Statins are lipid-lowering therapeutics with favorable anti-inflammatory profiles and have been proposed as an adjunct therapy for COVID-19. However, statins may increase the risk of SARS-CoV-2 viral entry by inducing ACE2 expression. Here, we performed a retrospective study on 13,981 patients with COVID-19 in Hubei Province, China, among which 1,219 received statins. Based on a mixed-effect Cox model after propensity score-matching, we found that the risk for 28-day all-cause mortality was 5.2% and 9.4% in the matched statin and non-statin groups, respectively, with an adjusted hazard ratio of 0.58. The statin use-associated lower risk of mortality was also observed in the Cox time-varying model and marginal structural model analysis. These results give support for the completion of ongoing prospective studies and randomized controlled trials involving statin treatment for COVID-19, which are needed to further validate the utility of this class of drugs to combat the mortality of this pandemic. Copyright © 2020 Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times